|
Match
|
Document |
Document Title |
|
|
8080522 |
Polyethlene glycol modifications of thymosin alpha-1
Polyethylene glycol modifications of thymosin alpha 1 (T&agr 1-PEGs), their preparation process, the medicine composition containing them, and their application in the medicine for preventing and...
|
|
|
8022036 |
Use of thymosin alpha 1 for the treatment of immunological diseases
It is described the use of thymosin alpha 1 for preparing a medicament useful for the prevention or treatment of graft-versus-host disease or graft rejection reactions in organ transplantation, in...
|
|
|
7897567 |
Methods of protecting against radiation damage using alpha thymosin
Damage to cells and/or a subject caused by radiation is treated or prevented by administration of an alpha thymosin peptide.
|
|
|
7816321 |
Thymosin β4 derivatives and use thereof
The present invention relates to thymosin β4 (Tβ4) derivatives, Gly-Tβ4 and Ala-Tβ4. The present invention further relates to a pharmaceutical composition comprising the said Tβ4 derivatives. The ...
|
|
|
7297676 |
Thymosin alpha 1 peptide/polymer conjugates
A pharmaceutical composition includes a physiologically active conjugate including a Thymosin alpha 1 (TA1) peptide conjugated to a material which increases half-life of the TA1 peptide in serum of...
|
|
|
7268118 |
Thymosin β4 compositions
A composition with a polypeptide including amino acid sequence LKKTET [SEQ ID NO:1] or a conservative variant thereof, the composition further including a carrier for application to a surface of a...
|
|
|
7208167 |
Treatment of hepatitis C with thymosin and peptide combination therapy
A method and pharmaceutical combination for treating hepatitis C by administering to a hepatitis C patient an effective amount of at least one alpha thymosin peptide, in combination with...
|
|
|
7109172 |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
The present invention relates to compounds of formula I or formula Ia or pharmaceutically acceptable salts thereof, that inhibit serine protease activity, particularly the activity of hepatitis C...
|
|
|
6733791 |
Sublingual compositions comprising thymosin fraction 5 and methods for administration thereof
Methods and compositions are described which allow for the sublingual absorption of peptides by oral administration. A liquid and a tablet format for the sublingual approach are demonstrated. The...
|
|
|
6602519 |
Oxidized thymosin β4
The present invention relates to the use of oxidized thymosin β4 in therapy, more particularly in the treatment of diseases or conditions associated with an inflammatory response of septic shock.
|
|
|
6495521 |
Combination therapy method for treating chronic hepatitis B
The present invention is aimed at augmenting the success rate of using thymosin in treatment of chronic hepatitis B, by employing a combination therapy using thymosin with antiviral agents which...
|
|
|
5939423 |
Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
Treatment of hepatitis B virus (HBV) infection in a patient by administering to the patient a drug regimen including an antiviral-effective amount of thymosin alpha 1 (Tα1) and an ...
|
|
|
5849696 |
Composition and method of treating hepatitis C
Compositions and methods of use for treating hepatitis C virus-infected mammals are disclosed. The compositions include one or more thymosins alone or in combination with one or more interferons....
|
|
|
5846548 |
Combined administration of mitogenic immumo stimulator and a thymomimetic
A method of tumor therapy involves controlling the immune system by co-administration of a mitogenic immuno-stimulating substance and a thymomimetic substance.
|
|
|
5643735 |
Anti-thymosin α1 monoclonal antibody-producing hybridoma
There are disclosed a hybridoma obtained by fusing a myeloma cell with an anti-thymosin α1 antibody-producing cell and selecting a hybridoma which produces a monoclonal antibody that recognizes ...
|
|
|
5632983 |
Method for treating secondary immunodeficiency
A method of treating cellular immune deficiency in a patient including the steps of determining the presence of a cellular immune deficiency and co-administering to the patient an effective amount...
|
|
|
5468729 |
Method for treatment of autoimmune hepatitis
A method and composition for treating autoimmune hepatitis in a patient utilizes an immunomodulatory amount of Tα1 and an anti-inflammatory amount of a corticosteroid.
|
|
|
5308833 |
Method for treating hepatitis B carriers with minimal disease
Methods for treating minimal disease hepatitis B infection are disclosed. Minimal disease carriers are given thymosin α-1, or biologically active fragments or analogs thereof In this way, the ...
|
|
|
4716148 |
Prothymosin alpha
A new biological polypeptide hormone has been isolated from mammalian thymus and has been given the designation prothymosin alpha. This peptide contains approximately 107 to 113 amino acid residues...
|
|
|
4696915 |
Parathymosin alpha
Parathymyosin alpha is a novel peptide isolated from mammalian thymus and contains approximately 105 amino acid residues. It bears a high degree of homology to prothymosin alpha both in sequence...
|
|
|
4670419 |
Pharmaceutical composition and its rectal use
A pharmaceutical composition containing a hydrophilic drug which is poorly absorbable through the gastrointestinal tract, and cyclodextrin, increases the absorbability of the drug into the...
|
|
|
4659696 |
Pharmaceutical composition and its nasal or vaginal use
A pharmaceutical composition containing a hydrophilic drug which is poorly absorbable through the gastrointestinal tract, and cyclodextrin, increases the absorbability of the drug into the...
|
|
|
4560676 |
Nα -desacetylthymosinα1 and process
The preparation of Nα -desacetylthymosinα1 and its use as a hormonally active agent participating in the regulation, differentiation and function of thymic dependent lymphocytes (T-cells) is d...
|
|
|
4500450 |
Polypeptide having an action on the immunological system, process for its isolation and purification, its use, agents containing this compound, and its cleavage products, their use and agents containing these products
The invention relates to a polypeptide which can be isolated from thymus glands and has an action on the immunological system, and which has a molecular weight of 3,480, a UV absorption with a...
|
|
|
4444757 |
Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
Methods are provided for the use of Thymus gland extracts, such as Thymosin, fraction 5, as an anti-autoimmune disease agent, useful in treating autoimmune diseases such as hypertension, lupus and...
|
|
|
4396605 |
Bis-thymosine α-1 compounds
Bis-thymosine α-1 consisting of two desacetylthymosine α-1 un N-terminally linked by a bridge bond of 1 to 10 carbon atoms, especially an α,ω-diacyl residue with 2 to 10 carbon atoms. This new com...
|
|
|
4395404 |
Synthetic thymosin β3 and β4 analogues
Novel peptides representing fragments of thymosin β3 and β4 have been synthesized and are active agents affecting regulation, differentiation and function of thymus dependent lymphocytes and m...
|
|
|
4388234 |
Peptide isolation
A process for isolating selected polypeptides from biological specimens. The process employs a guanidinium salt to treat frozen biological specimens from which selected polypeptides are to be...
|
|
|
4128637 |
Process for producing thymosin
Thymosin is produced by an improved process in which thymus glands are coarse ground, extracted in saline solution which is filtered and the filtrate or extract is injected with steam for a brief...
|
|
|
4079127 |
Thymosin alpha 1
The amino acid sequence of a biologically active polypeptide hormone isolated from calf thymus termed thymosin α1 has been determined. Thymosin α1 is a heat stable acidic molecule composed of 28 a...
|